Non-Hodgkin Lymphoma Clinical Trials in New York, New York

15 studies are recruiting for non-hodgkin lymphoma in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

    This study is a Phase 1 multicenter study with a Dose Escalation and Dose Expansion evaluating safety and efficacy of MT-601 administration to patients with Relapsed or Refractory Lymphoma. The starting dose administered is 200 x 10\^6 cells (flat dosing).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Cornell, New York, New York
    Locations
    7 in total
    Run by
    Marker Therapeutics, Inc.

    See if you can join NCT05798897 on ClinicalTrials.gov

  2. AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

    This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

    Stage
    Phase 1
    Ages
    12 and older
    Site
    Research Site, New York, New York
    Locations
    39 in total
    Run by
    AstraZeneca

    See if you can join NCT06137144 on ClinicalTrials.gov

  3. A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

    Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Medical Center, New York, New York
    Locations
    115 in total
    Run by
    BeOne Medicines

    See if you can join NCT05006716 on ClinicalTrials.gov

  4. Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

    This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL, r/r B-cell NHL and CLL/SLL.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, New York
    Locations
    15 in total
    Run by
    Imugene Limited

    See if you can join NCT03666000 on ClinicalTrials.gov

  5. Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

    This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of rondecabtagene autoleucel (ronde-cel) also known as LYL314, a dual-targeting chimeric antigen receptor (CAR) targeting cluster of differentiation (CD)19 and CD20 in participants with aggressive large B-cell ly…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    35 in total
    Run by
    Lyell Immunopharma, Inc.

    See if you can join NCT05826535 on ClinicalTrials.gov

  6. A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

    The purpose of this study is to collect voice recordings and nervous system (neurologic) assessments from people with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM) who are receiving standard treatment with CAR T-cell therapy. Researchers will study whether these voice recordings and assessmen…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York
    Locations
    8 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07249528 on ClinicalTrials.gov

  7. A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

    This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.

    Stage
    Not phased
    Ages
    Any age
    Site
    New York University Langone Medical Center, New York, New York
    Locations
    142 in total
    Run by
    Center for International Blood and Marrow Transplant Research

    See if you can join NCT01351545 on ClinicalTrials.gov

  8. Cord Blood Transplantation in Children and Young Adults With Blood Cancer

    The purpose of this study is to find out whether Cord Blood Transplantation/CBT as the first or second transplant is an effective treatment for children and young adults with blood cancer.

    Stage
    Phase 2
    Ages
    Up to 26
    Site
    Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07566377 on ClinicalTrials.gov

  9. A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib

    The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of the long-term safety and efficacy of pirtobrutinib after completion of clinical studies evaluating pirtobrutinib. The clinical studies that will feed into this master protocol are referred to as originator studie…

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York
    Locations
    38 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06876649 on ClinicalTrials.gov

  10. A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

    Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned stu…

    Stage
    Phase 4
    Ages
    18 and older
    Site
    Memorial Sloan-Kettering Cancer Center (MSKCC) - New York, New York, New York
    Locations
    36 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT06876662 on ClinicalTrials.gov

  11. Epco, Zanu, Ritux for R/R FL or MZL

    The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL) or marginal zone lymphoma (MZL). * The names of the study drugs involved in this research stud…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Locations
    3 in total
    Run by
    Reid Merryman, MD

    See if you can join NCT06563596 on ClinicalTrials.gov

  12. Study of SGR-1505 in Mature B-Cell Neoplasms

    The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Weill Cornell, New York, New York
    Locations
    36 in total
    Run by
    Schrödinger, Inc.

    See if you can join NCT05544019 on ClinicalTrials.gov

  13. In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET

    The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans ce…

    Stage
    EARLY_Phase 1
    Ages
    18 and older
    Site
    Memorial Sloan Kettering Cancer Center, New York, New York
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05093335 on ClinicalTrials.gov

  14. Amping up With PemJAK

    The purpose of this study is to understand and determine if ruxolitinib added to pembrolizumab is safe and effective for the treatment of relapsed or refractory Hodgkin and non-Hodgkin lymphomas.

    Stage
    Phase 2
    Ages
    18 to 95
    Site
    Columbia University Irving Medical Center, New York, New York
    Run by
    Seda S. Tolu

    See if you can join NCT07283822 on ClinicalTrials.gov

  15. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, New York, New York
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.